TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6387613

Group type: EXPERIMENTAL
Intervention: Human milk protein supplementation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Human milk supplemented with medium-chain triglyceride (MCT) oil
Number of subjects: 51
Study: 31659655

Group type: EXPERIMENTAL
Intervention: Pharmacists' recommendations accepted by PCPs
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pharmacists' recommendations made to PCPs
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Number of pharmacist recommendations
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Accepted recommendations
Number of subjects: 59
Study: 30472801

Group type: EXPERIMENTAL
Intervention: Probiotic intervention (Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve Bb99 and Propionibacterium freudenreichii)
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study: 28337899

Group type: EXPERIMENTAL
Intervention: Ketoprofen (single dose 30 minutes prior to extraction)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no drug administration before extraction)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 26407097

Group type: EXPERIMENTAL
Intervention: Performance-approach goals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Goals with no emphasis on social comparison
Number of subjects: 0
Study: 24145423

Group type: EXPERIMENTAL
Intervention: Pharmacological intervention targeting the neuroactive ligand-receptor interaction gene set
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21390581

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/(kg·d) for three days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (standard treatment and Chinese herbal decoction for purgation)
Number of subjects: 81
Study: 19641900

Group type: EXPERIMENTAL
Intervention: Anti-psychotic treatment (duration: 3 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anti-psychotic treatment (duration: 8 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anti-psychotic treatment (duration: 3 and 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 20
Study: 17662689

Group type: EXPERIMENTAL
Intervention: Self-help booklet (n=116)
Number of subjects: 347

Group type: COMPARATOR
Intervention: No self-help booklet (n=111)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Low scorers (n=120)
Number of subjects: 347
Study: 15128963

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual inpatient services
Number of subjects: 115
Study: 12064377

Group type: EXPERIMENTAL
Intervention: Enalapril/Hydrochlorothiazide 20/12.5 mg tablets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control formulation of Enalapril/Hydrochlorothiazide 20/12.5 mg tablets
Number of subjects: 20
Study: 10362894

Group type: EXPERIMENTAL
Intervention: Rivastigmine b.i.d.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 7887636

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: FAMTX
Number of subjects: 3

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 3
Study: 1684979

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 3437
Study: 6798049

Group type: EXPERIMENTAL
Intervention: Mechanical irrigation with a 10% mannitol solution
Number of subjects: 215

Group type: COMPARATOR
Intervention: Conventional preparations by digestive tract irrigation with or without intestinal antibiotics
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Addition of antibiotics (neomycin, metronidazole by mouth)
Number of subjects: 215
Study: 6235682

Group type: EXPERIMENTAL
Intervention: Combination preparation of benzoyl peroxide and miconazole cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzoyl peroxide and oral tetracycline
Number of subjects: 0
Study: 30354416

Group type: EXPERIMENTAL
Intervention: Dabigatran (NOAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (Control)
Number of subjects: 0
Study: 27638053

Group type: EXPERIMENTAL
Intervention: 300 IU of highly purified menotrophin as single subcutaneous and intramuscular doses
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 300 IU of highly purified urofollitrophin as single subcutaneous doses
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 225 IU of hp‐FSH as single subcutaneous doses
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: daily 225 IU of hp‐FSH as subcutaneous doses for 5 consecutive days
Number of subjects: 121
Study: 25055938

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day plus tegafur-uracil 400 mg/day (TU) for 2 years
Number of subjects: 169

Group type: COMPARATOR
Intervention: Tamoxifen plus doxorubicin (40 mg/m2) and cyclophosphamide (500 mg/m2) (ACT) for 2 years
Number of subjects: 169

Group type: COMPARATOR
Intervention: Tamoxifen plus doxorubicin and cyclophosphamide (ACT) for 2 years
Number of subjects: 169

Group type: COMPARATOR
Intervention: Tamoxifen plus doxorubicin and cyclophosphamide (ACT)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day plus tegafur-uracil 400 mg/day (TU)
Number of subjects: 169
Study: 22433757

Group type: EXPERIMENTAL
Intervention: Sunscreen intervention
Number of subjects: 0
Study: 20020333

Group type: EXPERIMENTAL
Intervention: Periarticular multimodal drug injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: No injection (Control)
Number of subjects: 64
Study: 18771405

Group type: EXPERIMENTAL
Intervention: 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 70% (v/v) isopropyl alcohol alone
Number of subjects: 0
Study: 15780172

Group type: EXPERIMENTAL
Intervention: Maximal Androgen Blockade (MAB)
Number of subjects: 0
Study: 14624403

Group type: EXPERIMENTAL
Intervention: CYP2D6*3 and *4 allele carriers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Poor metabolizers (PMs)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CYP2D6 genotyping assay
Number of subjects: 100
Study: 10563034

Group type: EXPERIMENTAL
Intervention: Alcohol administered (3 alcoholic drinks each containing approximately 10 g of pure alcohol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo administered (equivalent non-alcoholic beverage)
Number of subjects: 40
Study: 8951905

Group type: EXPERIMENTAL
Intervention: 99Tcm-MIBI from one of two radiopharmacies (exercise scans)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 99Tcm-MIBI from one of two radiopharmacies (rest scans)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 99Tcm-MIBI from one of two radiopharmacies (dipyridamole scans)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Exercise scans
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Rest scans
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Dipyridamole scans
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Clinical reports
Number of subjects: 303
Study: 1684155

Group type: EXPERIMENTAL
Intervention: RU 41,656 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Scopolamine 0.6 mg s.c.
Number of subjects: 12
Study: 6355542

Group type: EXPERIMENTAL
Intervention: Aspirin and sulfinpyrazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30778028

Group type: EXPERIMENTAL
Intervention: Topiramate, up to 100 mg daily for three months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Acupuncture, 12 sessions (3 sessions a week) for three months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA), 155-195 units for three months
Number of subjects: 66
Study: 30169112

Group type: EXPERIMENTAL
Intervention: Short time to surgery (TTS <48 hours)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Intermediate time to surgery (TTS 48-72 hours)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Long time to surgery (TTS >72 hours)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Short TTS
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Intermediate TTS
Number of subjects: 228

Group type: COMPARATOR
Intervention: Long TTS
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 228
Study: 26888724

Group type: EXPERIMENTAL
Intervention: GDM screening at general practitioners (GP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GDM screening at hospital settings
Number of subjects: 0
Study: 24731891

Group type: EXPERIMENTAL
Intervention: Lavender inhalation based on sesame oil
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (sesame oil only)
Number of subjects: 96
Study: 22134152

Group type: COMPARATOR
Intervention: LPV/r-based regimen (n = 99)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: NVP-based regimen (n = 96)
Number of subjects: 195
Study: 18930550

Group type: EXPERIMENTAL
Intervention: Intraoperative 5-fluorouracil (5-FU) 50 mg/ml for 5 minutes
Number of subjects: 103

Group type: COMPARATOR
Intervention: Intraoperative mitomycin C (MMC) 0.2 mg/ml for 2 minutes
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 17215195

Group type: EXPERIMENTAL
Intervention: Inulin (0.25 g/kg/d for 3 weeks)
Number of subjects: 14
Study: 15827896

Group type: EXPERIMENTAL
Intervention: L-carnitine 20 mg/kg, thrice weekly for 6 months
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 12118640

Group type: EXPERIMENTAL
Intervention: Sweeping of membranes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 120
Study: 9587725

Group type: EXPERIMENTAL
Intervention: Tramadol 3 mg kg‐1 (n = 20) administered intravenously at the beginning of wound closure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tramadol 3 mg kg‐1 (n = 20)
Number of subjects: 40
Study: 8790652

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, followed by 100 mg for the next nine days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 2839998

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fenfluramine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 8
Study: 4985446

Group type: EXPERIMENTAL
Intervention: Jet injection of diluted smallpox vaccine with a titre of 10(7) TCID(50)/ml
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Jet injection of diluted smallpox vaccine with a titre of 10(6) TCID(50)/ml
Number of subjects: 156

Group type: COMPARATOR
Intervention: Multiple-pressure inoculation of undiluted vaccine
Number of subjects: 156
Study: 31272265

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 86

Group type: COMPARATOR
Intervention: Longitudinal incision
Number of subjects: 86
Study: 28410087

Group type: EXPERIMENTAL
Intervention: Intervention arm (sedation management)
Number of subjects: 3438

Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 3438

Group type: EXPERIMENTAL
Intervention: Parents of Black children
Number of subjects: 3438

Group type: EXPERIMENTAL
Intervention: Parents of Hispanic children
Number of subjects: 3438

Group type: EXPERIMENTAL
Intervention: Parents of White children
Number of subjects: 3438
Study: 25459893

Group type: EXPERIMENTAL
Intervention: Naltrexone 50mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 24124428

Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle modification program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21356061

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) for 8 weeks followed by 24 weeks of dietary instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED)
Number of subjects: 0
Study: 19660515

Group type: EXPERIMENTAL
Intervention: Experimental mouth rinses with varying concentrations of tin (800 to 2800 ppm) and fluoride (250 to 500 ppm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available tin-containing mouth rinse (409 ppm Sn(2+), 250 ppm F(‐))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control group (no treatment)
Number of subjects: 0
Study: 17334580

Group type: EXPERIMENTAL
Intervention: Dengue antibody prevalence
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Reported case incidence during 1996, 1997, and 1998 epidemics
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Epidemiological surveillance data analysis
Number of subjects: 1260
Study: 15334857

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 U subcutaneously every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 U subcutaneously every 8 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-molecular-weight heparins
Number of subjects: 0
Study: 11710505

Group type: EXPERIMENTAL
Intervention: Vestibular exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (plus an antiviral agent?)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug treatment for viral inflammation
Number of subjects: 0
Study: 9024022

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate salt 12.5 mg
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate salt 25 mg
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate salt 50 mg
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 635
Study: 7908187

Group type: EXPERIMENTAL
Intervention: Intravenous beta‐blocking agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose‐insulin‐potassium (GIK) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer anticoagulant and antithrombotic agents (hirudin and Hirulog)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer thrombolytic drugs (recombinant plasminogen activator - r‐PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surfactant and emulsifying agents (Rheothrx)
Number of subjects: 0
Study: 3302654

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31331286

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (healthy diet)
Number of subjects: 0
Study: 29663389

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 24
Study: 25753889

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 68
Study: 24382836

Group type: EXPERIMENTAL
Intervention: Active Ultrasound (US)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo Ultrasound (US)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active Low-Level Laser Therapy (LLLT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo Low-Level Laser Therapy (LLLT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 60
Study: 23043572

Group type: EXPERIMENTAL
Intervention: High pressure port system
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard port system
Number of subjects: 94
Study: 19221039

Group type: EXPERIMENTAL
Intervention: WT1 mutations
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: WT1(mut)/FLT3-ITD(pos) genotype
Number of subjects: 617
Study: 17467848

Group type: EXPERIMENTAL
Intervention: gemcitabine 1250mg/m(2) plus cisplatin 70mg/m(2) (GC arm)
Number of subjects: 102

Group type: COMPARATOR
Intervention: gemcitabine 1000mg/m(2) plus vinorelbine 25mg/m(2) followed by gemcitabine 1000mg/m(2) plus ifosfamide 2000mg/m(2) (GV-GI arm)
Number of subjects: 102
Study: 15053911

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer (RMGIC) restorations
Number of subjects: 640

Group type: COMPARATOR
Intervention: Conventional glass ionomer (GIC) restorations
Number of subjects: 640
Study: 11935652

Group type: EXPERIMENTAL
Intervention: Immunocytochemistry for epithelial cytokeratin markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative monitoring of disseminated tumor cells in the bone marrow
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New molecular biology techniques for MRD phenotyping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for disseminated tumor cells
Number of subjects: 0
Study: 8181024

Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretic or low-dose loop diuretic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loop diuretic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large-dose loop diuretic combined with thiazide-type diuretic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous loop diuretic; short-term infusion of a loop diuretic; intensified combination oral diuretic therapy; intravenous positive inotropic therapy; ultrafiltration or dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrolyte replacement guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium retention score
Number of subjects: 0
Study: 2691821

Group type: EXPERIMENTAL
Intervention: 312 g of carbohydrate (H)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 45 g of carbohydrate (L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 156 g of carbohydrate (M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g of carbohydrate (P)
Number of subjects: 0
Study: 4557308

Group type: EXPERIMENTAL
Intervention: BX24 300 mg daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BX24 600 mg daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BX24 1200 mg daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Carbenoxolone sodium 300 mg daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BX24 300 mg daily with zinc sulphate 660 mg daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BX24 300 mg daily without zinc sulphate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Carbenoxolone sodium with zinc sulphate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitamin A 50,000 units daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vitamin A withheld
Number of subjects: 48
Study: 30772848

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) plus standard of care
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28766349

Group type: EXPERIMENTAL
Intervention: G-CSF administered at 10:00
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: G-CSF administered at 14:00
Number of subjects: 48
Study: 25500952

Group type: EXPERIMENTAL
Intervention: Cold exposure with fasting for 54 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold-stimulated glucose uptake in BAT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold exposure
Number of subjects: 0
Study: 24235214

Group type: EXPERIMENTAL
Intervention: Dietary vitamin D3 (1, 10, or 20 times the NRC recommended level of 200 IU/kg)
Number of subjects: 1872

Group type: COMPARATOR
Intervention: High stocking density (16 birds/m²)
Number of subjects: 1872
Study: 20732799

Group type: EXPERIMENTAL
Intervention: Soy isoflavones group (200 mg of Glycine max, 80 mg of isoflavone)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (1200 kcal diet and exercise)
Number of subjects: 87
Study: 19567350

Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/0.5g infused over 30 min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/1g infused over 30 min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AMX-SUL 2g/0.5g infused over 30 min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/1g infused over 3h
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/0.5g infused over 3h
Number of subjects: 4
Study: 16776849

Group type: EXPERIMENTAL
Intervention: oxidized mannan‐MUC1
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 12972984

Group type: EXPERIMENTAL
Intervention: Low-dose right unilateral electroconvulsive therapy (approximately 2.25 times seizure threshold)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-dose right unilateral electroconvulsive therapy (greater than 2.25 times seizure threshold)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Right unilateral electroconvulsive therapy (both doses)
Number of subjects: 54
Study: 10940089

Group type: EXPERIMENTAL
Intervention: Naratriptan (2.5 mg orally)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Sumatriptan (50 mg orally)
Number of subjects: 347
Study: 9009937

Group type: EXPERIMENTAL
Intervention: S&G/block (1% lidocaine bilateral GPN blocks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: S&G (2% viscous lidocaine swish and gargle)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: S&G/spray (2% viscous lidocaine swish and gargle + 10% lidocaine spray)
Number of subjects: 11
Study: 7932402

Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 76

Group type: COMPARATOR
Intervention: standard therapy (ampicillin, gentamicin and clindamycin)
Number of subjects: 76
Study: 3422562

Group type: EXPERIMENTAL
Intervention: Permucosal needle drainage
Number of subjects: 52

Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 52
Study: 30099402

Group type: EXPERIMENTAL
Intervention: Pain education
Number of subjects: 40

Group type: COMPARATOR
Intervention: Guideline-based physiotherapy treatment (control)
Number of subjects: 40
Study: 26632161

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) administration of eptifibatide
Number of subjects: 76

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of eptifibatide
Number of subjects: 76
Study: 25446521

Group type: EXPERIMENTAL
Intervention: Thenar palmar tape application with pressure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Thenar palmar tape application without pressure
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no taping)
Number of subjects: 45